Skip to content

Strybol Pharma Groep

Active
Private limited companyfounded 2011active for 14 yearsMaalse Steenweg 319, 8310 Brugge, BelgiumKBO/BCE: BE 0841.947.033

From the official registers: KBO 14 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Strybol Pharma Groep has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €391,741 and a net result of €282,396. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 22% of 12,737 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).

Risk analysisFollow ReportCompare
Strybol Pharma GroepActiveChecked score 83/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 16-12-2011 Normal situation
Legal form
Private limited company
Registered office
Maalse Steenweg 319, 8310 Brugge
Activity
Retail sale of pharmaceutical products NACE 47730
Establishment units
6 establishment units
Financial year end
31 December
Peppol
Reachable since 30-01-2025
Company details

Who decides

Board
  • Strybol InvestDirector · since 01-01-2012 · permanent representative STRYBOL Geert Gabriel Rosina
  • Strybol Iben PharmaDirector · since 23-12-2024 · permanent representative STRYBOL Iben Ebert Raven
  • Strybol Wout PharmaDirector · since 23-12-2024 · permanent representative STRYBOL Wout Jeroen Marc
Shareholders
Board & ownership

How it is doing

83 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.6%
Annual accounts 2025
Gross margin
€1.5m
▲ 21×
Turnover
≈ €3.7m
estimated
Profit
€282,396
▲ 331%
Equity
€391,741
▲ 258%
Total assets
€3.3m
▲ 19×
Staff
12.3 FTE
2025 accounts 29 days early
Filed on 02-07-2026at the National Bank
Financials
Why 83raises riskEquity €391,741 (11.9% of total assets)lowers riskFigures for financial year 2025 (filed 02-07-2026)Profit of €282,396 (financial year 2025)Founded in 2011Show the evidence

Checked score

Score 2025
83 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 63% of its sector peers (NACE 47, small)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Average
Solvency 37-50
equity 11.9% of total assets
Liquidity 44-8
short-term debt 26.2% · cash 3.1%
Profitability 79-21
return on assets 8.6%
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%

About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (3,694 companies, NACE 47, small)
Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.4%● unchanged vs 12-2024 02-2025: 0.4%● unchanged vs 01-2025 03-2025: 0.4%● unchanged vs 02-2025 04-2025: 0.5%▲ +0.1 percentage points vs 03-2025 05-2025: 0.5%● unchanged vs 04-2025 06-2025: 0.5%● unchanged vs 05-2025 07-2025: 0.7%▲ +0.2 percentage points vs 06-2025highest value 08-2025: 0.2%▼ -0.5 percentage points vs 07-2025 09-2025: 0.2%● unchanged vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025lowest value 02-2026: 0.2%● unchanged vs 01-2026lowest value 03-2026: 0.2%● unchanged vs 02-2026lowest value 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.2%● unchanged vs 05-2026 07-2026: 0.2%● unchanged vs 06-2026 08-2026: 0.6%▲ +0.4 percentage points vs 07-2026 09-2026: 0.6%● unchanged vs 08-2026 10-2026: 0.6%● unchanged vs 09-2026
Credit of up to €30,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.9, compared with 1.3 in 2024, above the usual 1.5; short-term debt: 26.2% and cash: 3.1% of total assets), but 88.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, small): better than 25% on solvency, 51% on liquidity, 77% on profitability and 98% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.
lowers riskraises riskneutral
raises risk · Equity €391,741 (11.9% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed 02-07-2026)
NBB · annual accounts
lowers risk · Profit of €282,396 (financial year 2025)
NBB · annual accounts
lowers risk · Founded in 2011
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 22% of 12737 sector peers (2025).
NBB · sector comparison
Position among 12737 sector peers
Solvency
better than 22%
← weakest strongest →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €391,741
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
29 days early
2024
8 days early
2023
29 days late
2022
28 days early
2021
33 days early
2020
31 days early
2019
2 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 15 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage

Key points

  • Positive: Result rose in 2025from €65,575 to €282,396 ▲ 331% View
  • Positive: Among the best 8% on net resultsector median €27,659 · 12,727 companies €282,396 View
  • Positive: 5 profitable years in a rowprofit 2025: €282,396 5 years View

Documents

Annual accounts at the NBB

All 14 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about Strybol Pharma Groep

What is the company number of Strybol Pharma Groep?
0841.947.033. In Belgium the VAT number is the company number with BE in front: BE 0841.947.033.
Where is Strybol Pharma Groep based?
The registered office is at Maalse Steenweg 319, 8310 Brugge.Company details
What does Strybol Pharma Groep do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of Strybol Pharma Groep?
Private limited company (BV).
When was Strybol Pharma Groep founded?
On 16-12-2011.
Is Strybol Pharma Groep still active?
Yes, Strybol Pharma Groep is an active enterprise in the KBO register.
How many employees does Strybol Pharma Groep have?
On average 12.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Strybol Pharma Groep?
≈ €3.7m in financial year 2025. Estimated from the gross margin of €1.5m: probably between €2.9m and €5.4m, based on 30 comparable companies, NACE 477.
Is Strybol Pharma Groep profitable?
In financial year 2025, Strybol Pharma Groep made a profit of €282,396.
Where can I find the annual accounts of Strybol Pharma Groep?
Strybol Pharma Groep filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of Strybol Pharma Groep due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to Strybol Pharma Groep

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure